BiomedicineNews.net

Biomedicine Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Search results for "Lymphoma"

A gene mutation may account for many cases of immune deficiency, in particular two syndromes known as immunoglobulin A ( IgA ) deficiency and Common Variable Immunodeficiency ( CVID ). The discover ...


The study found that survivors of stem-cell transplantation for blood cancers and case-matched controls reported similar rates of hospitalization and outpatient medical visits. They had similar rates ...


A new type of immunotherapy in which dendritic cells are tricked into action against cancer when they are exposed to harmless pieces of viruses and bacteria is described in the journal Cancer Research ...


Findings from an ongoing phase IIa study to evaluate the safety and efficacy of investigational chimeric antigen receptor T cell ( CART ) therapy CTL019 in certain types of relapsed or refractory ( r/ ...


The FDA ( Food and Drug Administration ) has approved Yescarta ( Axicabtagene ciloleucel ), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not ...


The U.S. Food and Drug Administration ( FDA ) has granted accelerated approval to Tecartus ( Brexucabtagene autoleucel, formerly KTE-X19 ), the first and only approved chimeric antigen receptor ( CAR ...


The U.S. Food and Drug Administration ( FDA ) has approved Breyanzi ( Lisocabtagene maraleucel; Liso-cel ), a CD19-directed chimeric antigen receptor ( CAR ) T cell therapy for the treatment of adult ...


The U.S. Food and Drug Administration ( FDA ) has granted accelerated approval to Yescarta ( Axicabtagene ciloleucel ) for the treatment of adult patients with relapsed or refractory follicular lympho ...